Hemogenyx Pharmaceuticals Share Discussion Threads

[premium beeks] 21/2/2024 20:19

Where's the surprise there? Do you think trials happen for free?Stop looking for reasons to back up.your bearish view, anyone who thinks some.kond of deal/placing isn't needed would be a berk.Surprised at why you do post such opinions though? I'm quite sure you have no position here.

[apotheki] 21/2/2024 14:55

Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC

· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.
· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000).

The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital.

The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners.

Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study.

The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

[jibba jabber] 20/2/2024 13:59

Hi Apotheki, yes of course thanks for the info, I was aware of the previous raises and as you say who knows? It's always difficult to gauge the entry point of course, I've gotten those wrong countless times now tbf, ha

[jibba jabber] 20/2/2024 13:39

Not gonna lie, somewhere around 2-2.5 would be a great entry point, I've been out of hemo for a long time now but these progressions look very attractive.

[loglorry1] 20/2/2024 11:25

Here comes the raise.... I guess placing more likely to be around 2.5p though.

[marcus80] 20/2/2024 11:11

No cash No business !! Placing at 3p ?

[apotheki] 20/2/2024 10:15

Perhaps just perhaps J J the Badger has [quite rightly in my opinion] been culled as it was well known vermin [aka a TROLL]

[jibba jabber] 20/2/2024 09:41

What happened to Badger did he get bored of trashing hemo daily?

[albert35911] 19/2/2024 16:16

There is a man in a white coat behind you

[steveberyl] 19/2/2024 15:14

Hemo will not rise by pennies, gradually over a few Month`s


The Day will dawn when Hemo rises by £££`s, Instantly. In it to benefit

[luckyabbeygale] 18/2/2024 16:08

Remember the President Putin comment about cancer vaccines should give a huge boost to cancer shares on Monday.

[steveberyl] 18/2/2024 15:57

HEMO Just got very interesting and the purpose of the last 3 RNS`s becomes obvious DISEASE X

World Health Organisation are ACTIVELY looking for Vaccines that may be in any stage that can produce the quantities in the event of a full blown Pandemic.

The plus side for Hemo is the fact that Hemo vaccine can be stored at virtual room temp and Shelf life is long term. Symptoms are MANYFOLD.

[dreamtwister] 17/2/2024 14:43

abbeygale is your middle name Lucy ?

[dreamtwister] 17/2/2024 14:36

Shame the Hemogenyx board of directors have not to this day financially

supported the Science.

[luckyabbeygale] 17/2/2024 14:31

I am voting all the posts as fairly as I can.

[apotheki] 17/2/2024 14:30

Sounds as though 2024 is going to be one hell of a year....

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.

Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options.

Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.

As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike.

Proactive interview::::

[dreamtwister] 17/2/2024 14:29

desperate attempt posting outdated articles lol

Gather around fellow investors Hemogenyx are listed on the main market & have used

their allowance to issue more Confectie...will Dr Sandler exercise his awarded

share options to raise funds ? Paper roses do not smell Sweet x

[loglorry1] 17/2/2024 14:23

They raised £534,375 before expenses (usually around 15%). That's a pathetic amount to raise and they need much much more for a phase 1 trial. It's probably £400K after expenses about 2 months burn.

They are skint and the recent PR pump is just to get some more money in. If you want to buy you might as well wait until after the raise which is 100% nailed on around the corner.

[apotheki] 17/2/2024 14:20

So adding September & November 2023 together a total of circa £1.25m was raised to add to the existing coffers.

One of those two fund raising was at a substantial premium which could potentially of course be replicated at some point!

[apotheki] 17/2/2024 14:16

18 September 2023

Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC

· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.
· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000). The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital.

The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners. Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study.

The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

[loglorry1] 17/2/2024 14:12

No, it sounds like a pre-raise pump they are skint!